Practical considerations for the use of SGLT2 inhibitors in patients with cardio, renal and metabolic conditions

This practical guidance document provides clinicians with a clear, evidence-based overview of the safe and effective use of SGLT2 inhibitors in patients with type 2 diabetes, chronic kidney disease, and chronic heart failure. It summarises key considerations for initiating therapy across eGFR ranges, managing concomitant medications, recognising when temporary treatment interruption is warranted, and addressing common side effects. The guidance also highlights follow-up recommendations, patient education points, and strategies to maximise clinical benefits while ensuring safety. Designed as a quick, user-friendly reference, it supports primary care professionals in integrating SGLT2 inhibitors into routine cardio-renal-metabolic management.

Access

Public

Year

2025